Workflow
舒泰神(300204) - 2020 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2020 was ¥54,881,413.35, a decrease of 68.19% compared to ¥172,527,399.28 in the same period last year[7] - Net profit attributable to shareholders was -¥24,737,997.53, representing a decline of 188.57% from ¥27,931,418.29 in the previous year[7] - Basic and diluted earnings per share were both -¥0.05, down 183.33% from ¥0.06 in the same period last year[7] - The company reported a net loss attributable to shareholders of 24.74 million yuan, a significant decline from a profit of 27.93 million yuan in the same period last year[21] - The company reported a total comprehensive loss of CNY 27,819,865.53 for Q1 2020, compared to a comprehensive income of CNY 35,037,209.26 in the same period last year[50] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 67.72% to ¥26,920,229.52 from ¥83,395,180.33 year-on-year[7] - Cash and cash equivalents decreased by 235.42 million yuan, a reduction of 66.77%, mainly due to the maturity of financial management funds from the previous period[17] - The company experienced a net cash decrease of 235,424,413.58 CNY during the quarter, compared to a decrease of 98,555,055.01 CNY in the previous year[58] - The company reported a cash and cash equivalents balance of 117,189,478.52 CNY at the end of the quarter, down from 266,646,312.52 CNY at the end of the previous year[58] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,794,619,414.79, a decrease of 3.64% from ¥1,862,413,759.94 at the end of the previous year[7] - Total liabilities decreased from CNY 227,182,478.72 to CNY 187,207,999.10, a decline of approximately 17.6%[41] - The total equity attributable to shareholders decreased from CNY 1,635,231,281.22 to CNY 1,607,411,415.69, a decline of about 1.7%[42] Research and Development - The company's research and development expenses increased compared to the previous year, despite the challenges posed by the pandemic[21] - Research and development expenses for Q1 2020 were CNY 33,630,508.18, slightly up from CNY 31,376,207.58 year-over-year[48] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,025[11] - The largest shareholder, Yizhao (Beijing) Pharmaceutical Technology Co., Ltd., held 37.21% of the shares, totaling 177,152,363 shares[11] Government Support and Other Income - The company reported non-recurring gains and losses totaling ¥9,922,293.19, primarily from government subsidies of ¥10,022,500.00[8] - The company's other income increased by 9.85 million yuan, a rise of 5709.81%, mainly due to receiving support funds from the Zhongguancun National Independent Innovation Demonstration Zone[18] Investment Activities - The total amount of raised funds is 83,159.29 million yuan, with 2,360.08 million yuan invested in the current quarter[29] - Cumulative investment of raised funds reached 50,223.06 million yuan, with a project completion rate of 92.14% for the first phase of the Shutaishen Pharmaceutical Industrial Base project[29] Market and Operational Risks - The company is facing risks related to the acceptance of new drugs in the market, which could impact financial performance if the drugs do not meet market demand[23] - There is a risk of talent shortage in the biopharmaceutical industry, prompting the company to enhance its human resource management and talent retention strategies[23] Management and Strategy - The company plans to strengthen market efforts and improve brand recognition to maintain competitiveness in the innovative drug market[24] - The company is committed to improving its management model and internal processes to mitigate management risks as it expands its operations[25] Compliance and Reporting - The company has not reported any violations regarding external guarantees during the reporting period[34] - The company has disclosed fundraising usage information accurately and completely without any violations[32] - The first quarter report for 2020 was not audited[70] - The company implemented new revenue and lease standards starting from 2020, with retrospective adjustments to prior comparative data[70]